Publication Name	World Journal of Gastroenterology
Manuscript ID	10671
Country	China

Received	2014-04-13 15:42
Peer-Review Started	2014-04-13 17:43
To Make the First Decision	2014-05-13 20:37
Return for Revision	2014-05-21 08:49
Revised	2014-05-22 00:00
Second Decision	2014-06-26 16:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-06-26 17:39
Articles in Press	2014-06-26 17:58
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-07-14 16:28
Typeset the Manuscript	2014-09-22 16:13
Publish the Manuscript Online	2014-10-07 17:32

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Review
Article Title	Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease
Manuscript Source	Unsolicited Manuscript
All Author List	Jiao-Ya Xu, Zhong-Ping Li, Li Zhang and Guang Ji
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 81273727 National Natural Science Foundation of China 81302927 Innovation Program of Shanghai Municipal Education Commission 14YZ054
Corresponding Author	Guang Ji, MD, Ph.D, Professor, Institute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China. jiliver@vip.sina.com
Key Words	Farnesoid X receptor; Non-alcoholic fatty liver disease; Mechanism; Therapy; Lipid metabolism
Core Tip	Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver disorders worldwide and has great risk potentials. While the mechanisms under NAFLD are still in the mist, farnesoid X receptor (FXR) provides a new aspect in this field. In addition to regulate bile acid metabolism, FXR can also be actively involved in lipid (cholesterol, triglyceride, fatty acid) and glucose metabolism, furthermore, FXR participates in regulating inflammation and NAFLD progression. Several FXR agonists are identified and both experimentally and clinically proved to be optimistic in preventing and treating NAFLD, indicating FXR quite a therapeutic target for NAFLD.
Publish Date	2014-10-07 17:32
Citation	Xu JY, Li ZP, Zhang L, Ji G. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(37): 13493-13500
URL	http://www.wjgnet.com/1007-9327/full/v20/i37/13493.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i37.13493

Full Article (PDF)	WJG-20-13493.pdf
Full Article (Word)	WJG-20-13493.doc
Manuscript File	10671-Review.docx
Answering Reviewers	10671-Answering reviewers.pdf
Copyright License Agreement	10671-Copyright assignment.pdf
Peer-review Report	10671-Scientific editor work list.pdf
Scientific Misconduct Check	10671-CrossCheck.jpg
Scientific Editor Work List	10671-Scientific editor work list.pdf